Capstone Therapeutics (CAPS) Projected to Post Quarterly Earnings on Tuesday

Capstone Therapeutics (NASDAQ:CAPS) is projected to release its Q4 2025 results before the market opens on Tuesday, April 7th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $12.5130 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, April 14, 2026 at 4:00 PM ET.

Capstone Therapeutics Stock Performance

NASDAQ:CAPS opened at $0.58 on Monday. The business’s 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.84. Capstone Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.29. The stock has a market cap of $5.25 million, a P/E ratio of -0.61 and a beta of -1.27. The company has a quick ratio of 0.35, a current ratio of 0.95 and a debt-to-equity ratio of 0.29.

Hedge Funds Weigh In On Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC bought a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 2.55% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Capstone Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.